AXR-270 cream / AxeroVision - LARVOL DELTA

[VIRTUAL] AxeroVision, Inc. (BIO 2021) - "Lead assets are AXR-159, a VLA-4 integrin antagonist being developed for the treatment of moderate to severe dry eye disease and with an acute onset of action in a phase 2a clinical study; and AXR-270, a highly potent and selective, pharmacologically differentiated corticosteroid in a proprietary once-daily topical ocular delivery formulation, being developed for the treatment of blepharitis. Both compounds have achieved clinical POC."

Dry Eye Disease • Inflammation • Ocular Inflammation • Ophthalmology

Evaluation of AXR-270 for the Treatment of Posterior Blepharitis Associated With Meibomian Gland Dysfunction (clinicaltrials.gov) - P2; N=129; Completed; Sponsor: AxeroVision, Inc.; Active, not recruiting ➔ Completed; Trial completion date: Oct 2021 ➔ Dec 2020

Clinical • Trial completion • Trial completion date • Dry Eye Disease • Ocular Infections • Ocular Inflammation • Ophthalmology

Evaluation of AXR-270 for the Treatment of Posterior Blepharitis Associated With Meibomian Gland Dysfunction (clinicaltrials.gov) - P2; N=129; Active, not recruiting; Sponsor: AxeroVision, Inc.; Recruiting ➔ Active, not recruiting; Trial completion date: Jun 2021 ➔ Oct 2021; Trial primary completion date: Jun 2021 ➔ Oct 2020

Clinical • Enrollment closed • Trial completion date • Trial primary completion date • Dry Eye Disease • Ocular Infections • Ocular Inflammation • Ophthalmology

Evaluation of AXR-270 for the Treatment of Posterior Blepharitis Associated With Meibomian Gland Dysfunction (clinicaltrials.gov) - P2; N=126; Recruiting; Sponsor: AxeroVision, Inc.

Clinical • New P2 trial • Dry Eye Disease • Ocular Infections • Ocular Inflammation • Ophthalmology